Interim Report Q1 2024 2024 off to a good start with continued revenue growth Revenue growth of 14% in Q1 2024, primarily arising from our key Cloud ERP Business Lines, Dynamics and M3. EBITDA amounted to DKK 55m, corresponding to an EBITDA margin of 12.4%. Excluding a net gain of DKK 20m from settlement of M3CS legal case, the EBITDA margin was 7.9%. Overall, a satisfactory start to the year. “We came off to a good start of the year driven by strong performance in our Cloud ERP business. Our customers’ focus on safeguarding critical business systems is currently reshaping demand, thus un...
>Good, in-line Q2 results driven by metal gains - Aurubis this morning released good, in-line Q2 2023-24 (ended 31 March) results with operating EBITDA at € 179m, 3% below ODDO BHF and 2% below company-compiled consensus. The figure improved 13% q-o-q despite lower TC/RCs for concentrate (the benchmark stepped down to $ 80 and 8ct/lb on January 1 from $ 88.8 and 8.8ct in 2023). The pick-up was mostly driven by higher metal gains on the back of recent solid development...
>Q1 2024 beating expectations, driven by Europe and the US - Ahold Delhaize reported net sales and underlying EBIT of € 21,728m and € 861m in Q1 2024 (ABNe: € 21,348m and € 802m, consensus: € 21,530m and € 809m). Comparable growth amounted to 0.8% in the US and 2.8% in Europe. We had forecast 0.6% and -0.2% and consensus was 0.0% and 2.2%, respectively. The group underlying operating profit margin amounted to 4.0% (flat year on year), compared with our forecast and co...
>CA T1 de 1.7 Md€ (vs 1.9 Md€e) – Marge d’EBITDA de 2.4% (vs 3%e) - Au titre de son T1 2024, Klöckner a publié hier des résultats légèrement inférieurs à nos attentes. Le CA ressort en retrait de 5.6% à 1 737 M€ (vs 1 900 M€e, consensus à 1 804 M€) du fait d’un effet prix négatif de 10.6% alors que les volumes sont en hausse de +5%. La marge brute atteint 297 M€ représentant 17% du CA, soit une légère hausse de 20 pb. En revanche, l’EBITDA baisse de 35.4% à 42 M€ (vs ...
Q1 sales and EBIT topped expectations in both of the group's geographies, continuing to demonstrate Ahold Delhaize's ability to preserve LfL growth and profitability during disinflationary times. We expect limited upgrades to consensus estimates prior to the CMD, but are betting more on a gradual r
>Good, in-line Q2 results driven by metal gains - Aurubis this morning released good, in-line Q2 2023-24 (ended 31 March) results with operating EBITDA at € 179m, 3% below ODDO BHF and 2% below company-compiled consensus. The figure improved 13% q-o-q despite lower TC/RCs for concentrate (the benchmark stepped down to $ 80 and 8ct/lb on January 1 from $ 88.8 and 8.8ct in 2023). The pick-up was mostly driven by higher metal gains on the back of recent solid development...
>STM suffered from a weak macro environment in Q2-23/24 - Stabilus released a mixed set of results for its Q2-23/24. Reported Group sales are +1% YOY to €314m (+1% vs. ODDO BHF & css.) with an organic growth rate of +1.0%. Sales are strongly up in APAC (+12% YOY), flat in EMEA and down in the Americas (-4%). In terms of market segment Aerospace, Marine & Rail (+66% YOY), Health, Recreation& Furniture (+6%) and Automotive (+5%) with especially Powerise are showing YOY ...
NPAT grew 8% yoy, in line with our and consensus expectations. Cellular phones and tablets (82% of ERAA’s total revenue) booked revenue growth of 13% yoy and gross profit growth of 10% yoy. ERAA had 2,095 stores (+13% yoy and +2% qoq) in 1Q24. Net profit growth could improve gradually after the relatively more aggressive store network expansion in the last few years. Maintain BUY with a target price of Rp520. • 1Q24 net profit up 8% yoy but down 23% qoq, … Erajaya Swasembada’s (ERAA) 1Q24 net p...
EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Schlagwort(e): Quartalsergebnis/Quartalsergebnis RHÖN-KLINIKUM AG startet mit gutem ersten Quartal ins Geschäftsjahr 2024 08.05.2024 / 08:59 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Corporate News Bad Neustadt a. d. Saale | 8. Mai 2024 RHÖN-KLINIKUM AG startet mit gutem ersten Quartal ins Geschäftsjahr 2024 Die RHÖN-KLINIKUM AG, einer der führenden Gesundheitsdienstleister in Deutschland, ist solide ins Geschäftsjahr 2024 gestartet. Sowohl das Konzernergebnis und EBITDA als au...
Edison Investment Research Limited Edison issues review on Canadian General Investments (CGI): Adding to positive long-term performance record 08-May-2024 / 07:56 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 8 May 2024 Edison issues review on Canadian General Investments (CGI): Adding to positive long-term performance record Canadian General Investments (CGI) has delivered a very commendable long-term performance versus the Canadian market. Longstanding manager Greg Eckel at Morgan Meighen & Associates (MMA) is unphased by sto...
EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Quarter Results/Quarter Results RHÖN-KLINIKUM AG starts financial year 2024 with a good first quarter 08.05.2024 / 08:59 CET/CEST The issuer is solely responsible for the content of this announcement. Corporate News Bad Neustadt a. d. Saale | 8 May 2024 RHÖN-KLINIKUM AG starts financial year 2024 with a good first quarter RHÖN-KLINIKUM AG, one of the leading healthcare providers in Germany, has made a solid start to financial year 2024. Both consolidated profit and EBITDA as well as revenues rose in the fi...
Camurus reported its Q1 2024 results, where i) total revenues came in at SEK 390m (vs css SEK 405m, -3.7%), of which SEK 364m product sales (+3% QoQ at CER), ii) profit before tax came in at SEK 97m (vs css 80.3m, +20%), and iii) a cash position at SEK 2,274m. We observe a steady increase in the nu
Four Directors at Parker Hannifin Corp sold after exercising options/sold 5,837 shares at between 536.490USD and 548.850USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by ...
A director at Sit S.p.A bought 22,500 shares at 2.171EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
>Q1 EBITDA pre of € 101m in line with consensus of € 98m - Group sales declined by 15% y-o-y to € 1,607m (css € 1,578m) including volume decline by 5.4% y-o-y (Q4 23: -12% y/y) but up 13% q-o-q. Price erosion was 9.2% y-o-y and just -1% q-o-q. EBITDA pre of € 101m was in line with consensus/ODDO BHF estimates of € 98m and down 47% y-o-y on a high comparison base. EBITDA pre regained slightly from € 97m in Q4 2023. Activity pick-up throughout Q1 pushed receivables, wei...
>AK de 4.25 M€ finalement - Vogo a annoncé hier la finalisation de son augmentation de capital ouverte du 18 avril au 2 mai, avec maintien du DPS. Au cours de cette opération, la société a pu lever finalement 4.25 M€ brut à travers l’émission de 1.05m d’actions nouvelles. Le prix de souscription était de 4.04 € par action, traduisant une décote de 17% sur le cours de clôture de la veille du lancement de l’opération (10 avril). Le montant levé est donc légèrement en d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.